Ate-Bev Early Response Prediction Model in Advanced HCC

Clinical trial NCT05763277 · RECRUITING

Trial details

NCT number: NCT05763277
Sponsor: Seoul National University Hospital
Status: RECRUITING
Study type: OBSERVATIONAL

Hepatocellular Carcinoma Atezolizumab-bevacizumab Response Evaluation

Start date: 2022-07-22
Primary completion: 2025-12-31
Enrollment: 170

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.